Pharma & Biotech - Page 25

Amgen has disclosed a significant cybersecurity breach in which hackers stole sensitive patient health information and proprietary company data from its cloud systems. The California-based drugmaker identified unauthorised activity within cloud storage

Curium has agreed to acquire all outstanding shares of Lantheus Holdings (LNTH) in a transaction that could be worth as much as $8 billion. Under the terms of the deal, Lantheus shareholders

Otsuka has reported positive full results from its Phase 3 VISIONARY trial, showing its drug Voyxact stabilised kidney function in adults with IgA nephropathy over two years. Voyxact, known clinically as sibeprenlimab-szsi,

The pharmaceutical industry has reached a pivotal moment at the midpoint of 2026, shaped by an accelerating dealmaking environment and rapidly shifting patient access dynamics. A widening gap in patient affordability is

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock transaction creating a major central nervous system biopharmaceutical company. The combined entity will generate approximately $2.2 billion in annual revenue,

The Section 232 pharmaceutical tariff regime is no longer a looming threat for the industry — it is now active law following the July 31, 2026, deadline. President Trump’s April 2, 2026,

A potential merger between AstraZeneca and Bristol Myers Squibb has been circulating on Wall Street, and the numbers involved are staggering. The Financial Times reported that the two pharmaceutical giants have held

Sanofi’s new chief executive Belén Garijo has spoken publicly for the first time about her plans to turn around the French pharmaceutical giant’s recent run of clinical disappointments. Garijo outlined a strategic

Viatris has received a formal rebuke from the US Food and Drug Administration over a direct-to-consumer video that allegedly misled viewers about the use of a cystic fibrosis inhaler. The FDA sent

Eli Lilly and contract manufacturer Resilience have committed $750 million to significantly expand production of Lilly’s KwikPen injectable device across its diabetes and obesity medicine portfolio. The investment will fund major upgrades